ImmunityBio gains as NCCN guidelines include new Anktiva indication

ImmunityBio $IBRX added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of its bladder cancer therapy, Anktiva.
Citing the updated 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer, ImmunityBio (IBRX) said that the medical group has recommended Anktiva with Bacillus Calmette-Guérin for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease.
The revised clinical guidelines expand the previous recommendation, which endorsed Anktiva with BCG for BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary disease, the company added.
According to ImmunityBio (IBRX), the update comes at a time when the FDA has yet to authorize the new indication under its approved indications for the immunotherapy.
However, the company plans to expand FDA approval for Anktiva to include the new indication after the regulator issued a Refusal to File letter for its supplemental Biologics License Application last year.